Compare AIRE & XCUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AIRE | XCUR |
|---|---|---|
| Founded | 2021 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.5M | 13.7M |
| IPO Year | 2023 | 2017 |
| Metric | AIRE | XCUR |
|---|---|---|
| Price | $1.48 | $1.70 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $1.30 | N/A |
| AVG Volume (30 Days) | ★ 44.0K | 43.1K |
| Earning Date | 04-28-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 60.34 | ★ 83.37 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,518,498.00 | N/A |
| Revenue This Year | $129.06 | N/A |
| Revenue Next Year | $83.72 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 376.42 | N/A |
| 52 Week Low | $0.16 | $1.43 |
| 52 Week High | $3.98 | $9.50 |
| Indicator | AIRE | XCUR |
|---|---|---|
| Relative Strength Index (RSI) | 30.96 | 31.68 |
| Support Level | $0.29 | N/A |
| Resistance Level | $2.17 | $3.40 |
| Average True Range (ATR) | 0.16 | 0.27 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 0.00 | 17.77 |
ReAlpha Tech Corp is a real estate technology company. The group is engaged in an end-to-end commission-free homebuying platform. It develops and utilizes its artificial intelligence-focused technology stack to empower retail investor participation in short-term rental properties, which are real estate units listed for a rental term. It provides short-term rental investment opportunities to everyday investors. The company has developed technologies and tools that allow for the analysis of short-term rental properties using AI to provide insight into that property's potential profitability and ways to increase such profitability. The company's reportable segments are Homebuying Services and the Technology Services segment.
Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.